Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Vogler et al. provided an overview of the current situation regarding HTA, pricing, and funding policies for point-of-care (POC) diagnostic tests for community-acquired acute respiratory tract infections (CA-ARTI) in 17 European countries by conducting a qualitative survey of healthcare authorities. In addition, the authors provided recommendations for improvement in decision-making processes.

Among other findings, the authors concluded that, in none of the 17 surveyed countries, the pricing and funding decisions for CA-ARTI diagnostics were based on HTA. The authors furthermore conclude that there is a need to strengthen pricing and funding policies for CA-ARTI diagnostics to increase their acceptance and use.

Access the full-text article here.